MULTIVARIANT META-ANALYSIS OF KRAS MUTATIONS'S PREDICTIVE VALUE FOR RESPONSE TO CETUXIMAB IN COLORECTAL CANCER

被引：0
|
作者：
Tsoukalas, N. [1 ,2 ]
Bagos, P. [2 ]
Hamodrakas, S. [2 ]
机构：
[1] 401 Gen Army Hosp, Athens, Greece
[2] Univ Athens, Fac Biol, Athens, Greece
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [1] Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer
    Tsoukalas, N.
    Tzovaras, A. A.
    Tolia, M.
    Kostakis, I. D.
    Papakostidi, A.
    Pistamaltzian, N.
    Ardavanis, A.
    JOURNAL OF BUON, 2012, 17 (01): : 73 - 78
  • [2] Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
    Qiu, Li-Xin
    Mao, Chen
    Zhang, Jian
    Zhu, Xiao-Dong
    Liao, Ru-Yan
    Xue, Kai
    Li, Jin
    Chen, Qing
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) : 2781 - 2787
  • [3] Kras mutations in colorectal cancer is a predictive factor of response and survival in patients treated with cetuximab
    Laurent-Puig, P.
    Livre, A.
    Boige, V
    Bachet, J.
    Ychou, M.
    Bouche, O.
    Pezet, D.
    Landi, B.
    Louvet, C.
    Andre, T.
    Ducreux, M.
    Rougier, P.
    Penault-Llroca, F.
    ANNALS OF ONCOLOGY, 2007, 18 : VII81 - VII81
  • [4] Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
    Petrelli, Fausto
    Borgonovo, Karen
    Cabiddu, Mary
    Ghilardi, Mara
    Barni, Sandro
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (07) : 823 - 833
  • [5] Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
    Fausto Petrelli
    Karen Borgonovo
    Mary Cabiddu
    Mara Ghilardi
    Sandro Barni
    International Journal of Colorectal Disease, 2011, 26 : 823 - 833
  • [6] Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
    Pietrantonio, Filippo
    Petrelli, Fausto
    Coinu, Andrea
    Di Bartolomeo, Maria
    Borgonovo, Karen
    Maggi, Claudia
    Cabiddu, Mary
    Iacovelli, Roberto
    Bossi, Ilaria
    Lonati, Veronica
    Ghilardi, Mara
    de Braud, Filippo
    Barni, Sandro
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (05) : 587 - 594
  • [7] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lièvre, A
    Bachet, JB
    Le Corre, D
    Boige, V
    Landi, B
    Emile, JF
    Côté, JF
    Tomasic, G
    Penna, C
    Ducreux, M
    Rougier, P
    Penault-Llorca, F
    Laurent-Puig, P
    CANCER RESEARCH, 2006, 66 (08) : 3992 - 3995
  • [8] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lievre, A.
    Bachet, J.
    Boige, V
    Landi, B.
    Emile, J.
    Cote, J.
    Tomasic, G.
    Rougier, P.
    Penault-Llorca, F.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 42 - 42
  • [9] Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab
    Jeeyun Lee
    Yong Sang Hong
    Jung Yong Hong
    Se Won Han
    Tae Won Kim
    Hye Jin Kang
    Tae You Kim
    Kyu-pyo Kim
    Suk Hyung Kim
    In-Gu Do
    Kyoung-Mee Kim
    Insuk Sohn
    Se Hoon Park
    Joon Oh Park
    Ho Yeong Lim
    Yong Beom Cho
    Woo Yong Lee
    Seong Hyeon Yun
    Hee Cheol Kim
    Young Suk Park
    Won Ki Kang
    Investigational New Drugs, 2014, 32 : 535 - 541
  • [10] Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab
    Lee, Jeeyun
    Hong, Yong Sang
    Hong, Jung Yong
    Han, Se Won
    Kim, Tae Won
    Kang, Hye Jin
    Kim, Tae You
    Kim, Kyu-pyo
    Kim, Suk Hyung
    Do, In-Gu
    Kim, Kyoung-Mee
    Sohn, Insuk
    Park, Se Hoon
    Park, Joon Oh
    Lim, Ho Yeong
    Cho, Yong Beom
    Lee, Woo Yong
    Yun, Seong Hyeon
    Kim, Hee Cheol
    Park, Young Suk
    Kang, Won Ki
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 535 - 541
12345